NZ HIV Medicine Research Review Issue 32

In this issue:

Test for integrase resistance in newly-diagnosed HIV?
Data support first-line, once daily raltegravir in HIV-1
Long-acting injectable cabotegravir + rilpivirine regimens
Bictegravir vs dolutegravir for initial HIV-1 therapy
. . . non-inferiority demonstrated in 2 trials
Low incidence of first viral rebound on ART
Screen PLWHIV for CVD risks
HBV, HCV and mortality among HIV+ persons
Which HIV ± HBV therapy for pregnant women?
TDF-based ART in pregnancy seems safe for women & infants
Financial incentives encourage ART adherence

Please login below to download this issue (PDF)